Showing 3501-3510 of 4075 results for "".
- Kenvue Launches Two New Tylenol Precise Pain-relieving Creamshttps://practicaldermatology.com/news/kenvue-launches-two-new-tylenol-precise-pain-relieving-creams/2461973/Kenvue Inc. is rolling out two new topical pain-relieving creams: Tylenol Precise Pain Relieving Cream and Tylenol Precise Cooling Pain Relieving Cream. These are among the first U.S. product launches from Kenvue since it became a publicly traded
- New Platform May Help Determine Which Melanoma Patients Will Respond to Immunotherapyhttps://practicaldermatology.com/news/new-platform-may-help-determine-which-melanoma-patients-will-respond-to-immunotherapy/2461949/A new approach that integrates a minimally invasive, painless microneedle platform may help monitor protein biomarkers in responses to a combination immunotherapy against melanoma. The platform is capable of absorbing the cell-surrounding, biomarker-containing fluid from deeper layers o
- Paradigm Therapeutics Acquires Late Stage "Breakthrough Therapy" for Treatment of All Subtypes of EBhttps://practicaldermatology.com/news/paradigm-therapeutics-acquires-late-stage-breakthrough-therapy-for-treatment-of-all-subtypes-of-eb/2461948/Paradigm Therapeutics Inc. now has the worldwide rights of SD-101, a topical whole-body treatment for all subtypes of Epidermolysis Bullosa (EB), from Amicus Therapeutics. Terms of the deal have not been disclosed. SD-101 received Rare Pediatric Disease designation&
- First Patient Dosed in Phase 1/2a Trial of AGLE-102 to Treat Severe Second-degree Burnshttps://practicaldermatology.com/news/first-patient-dosed-in-phase-12a-trial-of-agle-102-to-treat-severe-second-degree-burns/2461938/The first patient has been dosed in Aegle Therapeutics Corp.’s Phase 1/2a clinical trial of AGLE-102 for the treatment of severe second-degree burns. AGLE-102 is an investigational product comprised of native extracellular vesicles isolated from allogeneic stem cel
- DermWire’s Practical Guide to Assessing Quality of Life and Mood in Patients With Chronic Skin Diseaseshttps://practicaldermatology.com/news/dermwires-practical-guide-to-assessing-quality-of-life-and-mood-in-patients-with-chronic-skin-diseases/2461936/Psoriasis, atopic dermatitis (AD), hidradenitis suppurativa (HS), and other dermatological conditions often go more than skin deep and can have profound effects on a patient's quality of life, mood, and mental health. This is the main takeaway from a panel discussion on the psy
- Verrica's Injectable Oncolytic Peptide Clears BCC in Early Phase 2 Datahttps://practicaldermatology.com/news/verricas-injectable-oncolytic-peptide-clears-bcc-in-early-phase-2-data/2461925/Verrica Pharmaceuticals Inc.’s VP-315 can clear basal cell carcinoma (BCC), according to data from Part 1 of an ongoing Phase 2 study presented at the 2023 American Academy of Dermatology Innovation Academy in Tampa, Fla. Given via injection into the tumor, VP-315 is an oncolytic
- UF Researcher Recognized for Life’s Work on Neurofibromatosishttps://practicaldermatology.com/news/uf-researcher-recognized-for-lifes-work-on-neurofibromatosis/2461922/Margaret “Peggy” Wallace, PhD, a professor in the department of molecular genetics and microbiology in the University of Florida College of Medicine, has received an award from the Children’s Tumor Foundation in recognition of her significant contributions to neurofibromatosis r
- Positive Topline Data Seen in Phase II Trial of LNK01001 in ADhttps://practicaldermatology.com/news/positive-topline-data-seen-in-phase-ii-trial-of-lnk01001-in-ad/2461916/Lynk Pharmaceuticals Co., Ltd.’s LNK01001 performed well in a Phase II clinical trial for the treatment of atopic dermatitis (AD), according to positive topline data from the Company. LNK01001 is a highly selective JAK1 inhibitor that blocks JAK1 without crossing over onto ot
- Golfers Face Higher Risk for Skin Cancerhttps://practicaldermatology.com/news/golfers-face-higher-risk-for-skin-cancer/2461902/New research from the University of South Australia shows that golfers have a higher risk of skin cancer when compared to the general population. Fully 27% of golfers – or one in four – had been diagnosed with skin cancer, as compared with 7% of the gener
- Study Cites Surge in Google Searches for Skin of Color Sunscreenshttps://practicaldermatology.com/news/study-cites-surge-in-google-searches-for-skin-of-color-sunscreens/2461891/Growing numbers of people are searching for sunscreen for dark skin and sunscreen for black skin on Google, a new study shows. The estimated annual relative search volume (RSV) for "sunscreen for dark skin" ranged from 0 to 28, with the peak being reached in 2020.&nb